References

CAR T therapy beyond cancer: the evolution of a living drug

10.1038/s41586-023-06243-w · 2023 · External reference

CAR T cell combination therapies to treat cancer

10.1016/j.ccell.2024.07.002 · 2024 · External reference

Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review

10.1001/jamaoncol.2023.4504 · 2024 · External reference

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

10.1038/s41591-018-0010-1 · 2018 · External reference

Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma

10.1158/2643-3230.bcd-22-0018 · 2022 · External reference

A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity

10.1126/sciimmunol.abd4344 · 2021 · External reference

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

10.1126/science.abc3421 · 2020 · External reference

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients

10.1126/science.abf3363 · 2021 · External reference

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

10.1126/science.aan3706 · 2018 · External reference

The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells

10.18632/oncotarget.22953 · 2017 · External reference

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy

10.1016/j.ymthe.2023.01.012 · 2023 · External reference

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

10.1038/s41591-022-01702-9 · 2022 · External reference

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

10.1182/blood.2024025366 · 2025 · External reference

Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency

10.1158/2159-8290.cd-24-1230 · 2025 · External reference

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

10.1038/s41591-023-02234-6 · 2023 · External reference

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

10.1038/s41467-022-32960-3 · 2022 · External reference

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

10.1038/s41591-023-02453-x · 2023 · External reference

Fecal microbiota transplantation: current challenges and future landscapes

10.1128/cmr.00060-22 · 2024 · External reference

Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis

10.1038/s41467-024-53144-1 · 2024 · External reference

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

10.1038/s41467-020-16079-x · 2020 · External reference

Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo

10.1038/s41423-020-0429-4 · 2021 · External reference

A syngeneic mouse B-cell lymphoma model for pre-clinical evaluation of CD19 CAR T cells

10.3791/58492 · 2018 · External reference

Mfuzz: a software package for soft clustering of microarray data

10.6026/97320630002005 · 2007 · External reference

Functional interpretation of single cell similarity maps

10.1038/s41467-019-12235-0 · 2019 · External reference

Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses

10.1126/sciimmunol.abb4432 · 2020 · External reference

PD-L1 restrains PD-1+Nrp1lo Treg cells to suppress inflammation-driven colorectal tumorigenesis

10.1016/j.celrep.2024.114819 · 2024 · External reference

Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiota-dependent manner

10.7150/thno.43716 · 2020 · External reference

Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt

10.1002/mnfr.201500187 · 2015 · External reference

Randomized placebo-controlled, biomarker-stratified phase ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity

10.1158/2159-8290.cd-24-0066 · 2024 · External reference

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

10.1186/s12943-024-02079-8 · 2024 · External reference

Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

10.1136/jitc-2021-003351 · 2021 · External reference

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

10.1016/j.cell.2023.06.002 · 2023 · External reference

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

10.1016/j.cell.2023.03.011 · 2023 · External reference

The microbial metabolite desaminotyrosine protects from influenza through type I interferon

10.1126/science.aam5336 · 2017 · External reference

Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity

10.1016/j.immuni.2022.01.006 · 2022 · External reference

Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity

10.1016/j.cmet.2021.03.002 · 2021 · External reference

Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib

10.1080/19490976.2024.2410474 · 2024 · External reference

The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt+Treg and PD-1 blockade efficacy

10.1080/19490976.2024.2315631 · 2024 · External reference

Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission

10.1038/s41586-024-07762-w · 2024 · External reference

TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion

10.1073/pnas.1905675116 · 2019 · External reference

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

10.1038/s41586-021-04390-6 · 2022 · External reference

CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype

10.1136/jitc-2023-007803 · 2023 · External reference

ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses

10.1084/jem.20231820 · 2024 · External reference

Nutrient-driven histone code determines exhausted CD8+ T cell fates

10.1126/science.adj3020 · 2025 · External reference

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer

10.1038/s41467-021-24331-1 · 2021 · External reference

Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell

10.1080/19490976.2023.2249143 · 2023 · External reference

Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?

10.1016/j.xcrm.2021.100328 · 2021 · External reference

The potential of the gut microbiota and butyrate to enhance CAR T-cell therapy in non-hodgkin lymphoma

10.1158/1078-0432.ccr-25-1676 · 2026 · External reference

The controversial role of human gut Lachnospiraceae

10.3390/microorganisms8040573 · 2020 · External reference

Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity

10.1038/s41556-024-01462-3 · 2024 · External reference